Celgene Pays Acceleron $25M up front under anaemia drug partnership
This article was originally published in Scrip
Executive Summary
Celgene is paying privately held Acceleron Pharma $25 million up front under a deal to jointly develop and commercialise ACE-536, a ligand trap that inhibits members of the transforming growth factor- (TGF) beta "superfamily" involved in the late stages of erythropoiesis – the process of generating red blood cells – as a treatment for anaemia.